Cardio-Oncology Education and Training: JACC Council Perspectives

Cardio-Oncology Education and Training: JACC Council Perspectives

The development of innovative cancer therapies has led to unprecedented improvement in survival outcomes and diverse treatment-related toxicities, including those with cardiovascular in nature. Aging population further increase the number of patients being treated for cancer, especially those with comorbidities. As existing and developing cardiovascular disease poses some the greatest risk of morbidity and mortality in patients with cancer.

Addressing the needs of complex cardiovascular patients has become increasingly important, which resulted in important for intersecting disciplines: cardio-oncology. Over the past decade, there has been a remarkable improvement of cardio-oncology clinics and service lines. This development, however, has occurred in a vacuum practice guidelines and training standards, although these are being actively pursued. In the document the board’s perspective, the authors describe the scope of practice in oncology and cardio-training requirements proposed, and the core competencies required. This document also serves as a road map to confirm cardio-oncology as a subspecialty of medicine.

The use of biomarkers to guide the selection of patients and therapies have gained a lot of attention to improving the scope and complexity of the selection of targeted therapy and immunotherapy. Clinical trials provide the basis for the discovery of biomarkers, which can then help in the development of new drugs. For that, a sample of cancer patients, including DNA, RNA, proteins, and metabolome isolated from cancerous tissue and blood or urine, is analyzed in a variety of ways to identify relevant biomarkers. In conjunction with the nucleotide-based, high-throughput, next-generation sequencing techniques, therapy-guided tests rely immunohistochemistry biomarker-based proteins play an important role in cancer treatment. In this review, we discuss the current knowledge of DNA and protein biomarkers for cancer immunotherapy.

both the primary and recurrence of cancer in patients after resection of colorectal cancer: An analysis of the integrated test with the Japan Clinical Oncology Group: JCOG1702A

Background: Improved early detection and treatment have resulted in an increase in the number of long-term victims of colorectal cancer (CRC). For the victims, a second primary cancers and recurrences are important issues; However, the evidence for the study of appropriate control strategies limited.This remnants aims to determine the frequency and timing of a second primary cancer in patients after surgery to explore the appropriate control strategies using an integrated analysis of three large-scale randomized controlled trials in Japan.

Methods: The eligibility criteria of the three trials included histologically confirmed CRC and receive operations. Time, location and frequency of second primary cancers and recurrences investigated. risk factors associated with a second primary cancer were also examined. standard incidence ratio (SIR) of a second primary cancer in comparison to the national database of the Cancer Registry of Japan is expected.
Results: A total of 2824 patients were included in this study. The cumulative incidence of second primary cancers increased from time to time. SIR of each second primary cancer was 1.07 (95% CI: 0.94 to 1.21). SIR for second primary cancers intestine was 1.09 (95% CI: 0.79 to 1.47). The cumulative incidence of recurrence nearly reached a plateau at 3 years.

Conclusions: A strategy for the general supervision of the general population can be applied even to patients curatively resected CRC, as a second primary cancer risk is nearly the same as the general population.

 Cardio-Oncology Education and Training: JACC Council Perspectives
Cardio-Oncology Education and Training: JACC Council Perspectives

Adherence to Oral Anticancer Therapeutics in Gynecologic Oncology Population

Introduction: To get a better understanding of gynecologic oncology patient compliance with oral anticancer agents through both cross-sectional survey of compliance and qualitative interviews with patients and physicians about their experiences with the drug.
Methods: Participants were eligible completing the survey for this cross-sectional study that included an assessment of compliance, distress, quality of life, and health literacy. Each woman takes oral anticancer agent for gynecological malignancies in a tertiary academic medical center for 30 days or more to qualify. semi-structured qualitative interviews (n = 14) was then performed to explore the experience with oral anticancer agent. We also perform qualitative group interviews with doctors and nurse practitioners.

Results: One hundred women taking oral anticancer agent listed. Fifty-four percent reported perfect adherence to their treatment, 21% reported a vague compliance (indicating at least one nonadherent behavior in the previous 7 days), and 25% reported non-compliance (indicating more than one behavior nonadherent within 7 days in advance). Qualitative analysis identified five main themes: the ease of use compared to traditional therapies; drugs self-administered mental burden; the perceived importance of the drug; management of side effects; and the desire for physician communication consistent. common misperception stated in an interview health care professionals including the high adherence to oral medication and a belief that the cost is the biggest barrier to compliance.

PLGF-1, human recombinant

4739-100 each
EUR 836.4

PLGF-1, human recombinant

4739-1000 each
EUR 3909.6

PLGF-1, human recombinant

4739-25 each
EUR 307.2

PLGF-2, human recombinant

4741-10 each
EUR 307.2

PLGF-2, human recombinant

4741-1000 each
EUR 4105.2

PLGF-2, human recombinant

4741-50 each
EUR 874.8

PLGF-3 Human Recombinant

P1563-10 10 µg
EUR 211.2

PLGF-3 Human Recombinant

P1563-50 50 µg
EUR 661.2

Human Caspase peptide-17(Caspase peptide-17)

QY-E05408 96T
EUR 433.2

Human Anti cyclic cirtullinated peptide ELISA kit

E01C0708-192T 192 tests
EUR 1524
Description: A competitive ELISA for quantitative measurement of Human Anti cyclic cirtullinated peptide in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Human Anti cyclic cirtullinated peptide ELISA kit

E01C0708-48 1 plate of 48 wells
EUR 624
Description: A competitive ELISA for quantitative measurement of Human Anti cyclic cirtullinated peptide in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Human Anti cyclic cirtullinated peptide ELISA kit

E01C0708-96 1 plate of 96 wells
EUR 822
Description: A competitive ELISA for quantitative measurement of Human Anti cyclic cirtullinated peptide in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

PLGF(PLGF93) Antibody

BNCA0093-250 250uL
EUR 459.6
Description: Primary antibody against PLGF(PLGF93), APC conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNCA0094-250 250uL
EUR 459.6
Description: Primary antibody against PLGF(PLGF94), APC conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC800093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), CF680 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC800093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), CF680 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC800094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), CF680 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC800094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), CF680 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC810093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), CF680R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC810093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), CF680R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC810094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), CF680R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC810094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), CF680R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC940093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), CF594 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC940093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), CF594 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC940094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), CF594 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC940094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), CF594 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC880093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), CF488A conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC880093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), CF488A conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC880094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), CF488A conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC880094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), CF488A conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC430093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), CF543 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC430093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), CF543 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC430094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), CF543 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC430094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), CF543 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC400093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), CF640R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC400093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), CF640R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC400094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), CF640R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC400094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), CF640R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC050093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), CF405M conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC050093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), CF405M conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC050094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), CF405M conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC050094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), CF405M conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNCB0093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), Biotin conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNCB0093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), Biotin conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNCB0094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), Biotin conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNCB0094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), Biotin conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNCAP0093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNCAP0093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNCAP0094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNCAP0094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNCR0093-250 250uL
EUR 459.6
Description: Primary antibody against PLGF(PLGF93), RPE conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNCR0094-250 250uL
EUR 459.6
Description: Primary antibody against PLGF(PLGF94), RPE conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNUB0093-100 100uL
EUR 250.8
Description: Primary antibody against PLGF(PLGF93), Concentration: 0.2mg/mL

PLGF(PLGF93) Antibody

BNUB0093-500 500uL
EUR 549.6
Description: Primary antibody against PLGF(PLGF93), Concentration: 0.2mg/mL

PLGF(PLGF94) Antibody

BNUB0094-100 100uL
EUR 250.8
Description: Primary antibody against PLGF(PLGF94), Concentration: 0.2mg/mL

PLGF(PLGF94) Antibody

BNUB0094-500 500uL
EUR 549.6
Description: Primary antibody against PLGF(PLGF94), Concentration: 0.2mg/mL

PLGF(PLGF93) Antibody

BNCP0093-250 250uL
EUR 459.6
Description: Primary antibody against PLGF(PLGF93), PerCP conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNCP0094-250 250uL
EUR 459.6
Description: Primary antibody against PLGF(PLGF94), PerCP conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNUM0093-50 50uL
EUR 474
Description: Primary antibody against PLGF(PLGF93), 1mg/mL

PLGF(PLGF94) Antibody

BNUM0094-50 50uL
EUR 474
Description: Primary antibody against PLGF(PLGF94), 1mg/mL

PLGF(PLGF93) Antibody

BNCH0093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNCH0093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNCH0094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNCH0094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC040093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), CF405S conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC040093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), CF405S conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC040094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), CF405S conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC040094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), CF405S conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC550093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), CF555 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC550093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), CF555 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC550094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), CF555 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC550094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), CF555 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC610093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), CF660R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC610093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), CF660R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC610094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), CF660R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC610094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), CF660R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC680093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), CF568 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC680093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), CF568 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC680094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), CF568 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC680094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), CF568 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC470093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), CF647 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC470093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), CF647 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC470094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), CF647 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC470094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), CF647 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC700093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), CF770 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC700093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), CF770 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC700094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), CF770 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC700094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), CF770 conjugate, Concentration: 0.1mg/mL

Human PLGF ELISA kit

LF-EK50333 1×96T
EUR 777.6

Human PLGF ELISA Kit

EHP0025 96Tests
EUR 625.2

Human Brain Natriuretic Peptide (BNP) Peptide

20-abx065599
  • EUR 878.40
  • EUR 343.20
  • EUR 2766.00
  • EUR 1062.00
  • EUR 627.60
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Brain natriuretic peptide (BNP) Peptide

abx670010-01mg 0.1 mg
EUR 360

Human Osteogenic Growth Peptide (OGP) Peptide

20-abx652290
  • EUR 661.20
  • EUR 292.80
  • EUR 1914.00
  • EUR 777.60
  • EUR 493.20
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Atrial Natriuretic Peptide (ANP) Peptide

20-abx652084
  • EUR 693.60
  • EUR 309.60
  • EUR 2064.00
  • EUR 828.00
  • EUR 510.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

PLG Blocking Peptide

DF4837-BP 1mg
EUR 234

Peptide YY (PYY) (Human) antibody

Y072 50 ul
EUR 512.4
Description: The Peptide YY (PYY) (Human) antibody is available in Europe and for worldwide shipping via Gentaur.

Anti-Flt1 Peptide

20-abx265801
  • EUR 393.60
  • EUR 594.00
  • EUR 326.40
  • 10 mg
  • 25 mg
  • 5 mg

Anti-Flt1 Peptide

5-00708 4 x 5mg Ask for price

Human cathelicidin antimicrobial peptide (CAMP) Control/blocking peptide

AB-23041-P 100ug
EUR 196.8

PLGF ELISA KIT|Human

EF000015 96 Tests
EUR 826.8

Human C- Peptide, connecting peptide ELISA Kit

CELI-66099h 96 Tests
EUR 988.8

Human Glucagon-Like Peptide 2 (GLP2) Peptide

abx670345-1mg 1 mg
EUR 427.2

Human Amyloid Beta Peptide 1-40 (Ab1-40) Peptide

20-abx652283
  • EUR 376.80
  • EUR 243.60
  • EUR 927.60
  • EUR 410.40
  • EUR 309.60
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Amyloid Beta Peptide 1-40 (Ab1-40) Peptide

abx670346-1mg 1 mg
EUR 627.6

Human Vasoactive Intestinal Peptide (VIP) Peptide

20-abx069654
  • EUR 794.40
  • EUR 326.40
  • EUR 2448.00
  • EUR 944.40
  • EUR 577.20
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Vasoactive Intestinal Peptide (VIP) Peptide

20-abx652275
  • EUR 693.60
  • EUR 309.60
  • EUR 2013.60
  • EUR 811.20
  • EUR 510.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Proinsulin C Peptide (33-63) Antibody

11041-05011 150 ug
EUR 260.4

Human Proinsulin C peptide (55-89) Antibody

11731-05011 150 ug
EUR 260.4

Human C-Type Natriuretic Peptide (NPPC) Peptide

20-abx066173
  • EUR 744.00
  • EUR 326.40
  • EUR 2230.80
  • EUR 878.40
  • EUR 543.60
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Brain Natriuretic Peptide (BNP) Peptide (BSA)

20-abx651076
  • EUR 393.60
  • EUR 243.60
  • EUR 1011.60
  • EUR 477.60
  • EUR 326.40
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Brain Natriuretic Peptide (BNP) Peptide (OVA)

20-abx651077
  • EUR 693.60
  • EUR 309.60
  • EUR 2064.00
  • EUR 828.00
  • EUR 510.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Brain Natriuretic Peptide (BNP) Peptide (OVA)

20-abx651078
  • EUR 309.60
  • EUR 226.80
  • EUR 678.00
  • EUR 343.20
  • EUR 276.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Brain Natriuretic Peptide (BNP) Peptide (OVA)

20-abx651079
  • EUR 326.40
  • EUR 226.80
  • EUR 727.20
  • EUR 360.00
  • EUR 276.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Brain Natriuretic Peptide (BNP) Peptide (OVA)

20-abx651080
  • EUR 309.60
  • EUR 226.80
  • EUR 678.00
  • EUR 343.20
  • EUR 276.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Gastrin Releasing Peptide (GRP) Peptide (BSA)

20-abx651228
  • EUR 493.20
  • EUR 260.40
  • EUR 1262.40
  • EUR 560.40
  • EUR 360.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human anti cyclic citrullinated peptide antibody ELISA kit

E01A2058-192T 192 tests
EUR 1524
Description: A competitive ELISA for quantitative measurement of Human anti cyclic citrullinated peptide antibody in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Human anti cyclic citrullinated peptide antibody ELISA kit

E01A2058-48 1 plate of 48 wells
EUR 624
Description: A competitive ELISA for quantitative measurement of Human anti cyclic citrullinated peptide antibody in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Human anti cyclic citrullinated peptide antibody ELISA kit

E01A2058-96 1 plate of 96 wells
EUR 822
Description: A competitive ELISA for quantitative measurement of Human anti cyclic citrullinated peptide antibody in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Peptide YY, Human

5-01749 4 x 1mg Ask for price

Peptide YY (human)

H-9180.0500 0.5mg
EUR 400.8
Description: Sum Formula: C194H295N55O57; CAS# [118997-30-1] net

Peptide YY (human)

H-9180.1000 1.0mg
EUR 618
Description: Sum Formula: C194H295N55O57; CAS# [118997-30-1] net

Human Glucagon Like Peptide 2 (GLP2) Peptide (OVA)

20-abx651238
  • EUR 543.60
  • EUR 276.00
  • EUR 1462.80
  • EUR 627.60
  • EUR 393.60
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Glucagon Like Peptide 2 (GLP2) Peptide (OVA)

20-abx165542
  • EUR 693.60
  • EUR 309.60
  • EUR 2064.00
  • EUR 828.00
  • EUR 510.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Anti-Kentsin Peptide

20-abx265748
  • EUR 393.60
  • EUR 594.00
  • EUR 326.40
  • 10 mg
  • 25 mg
  • 5 mg

Human anti-cyclic citrullinated peptide,CCP ELISA Kit

201-12-0564 96 tests
EUR 528
Description: A quantitative ELISA kit for measuring Human in samples from biological fluids.

Human anti-cyclic citrullinated peptide,CCP ELISA Kit

CN-04354H1 96T
EUR 556.8

Human anti-cyclic citrullinated peptide,CCP ELISA Kit

CN-04354H2 48T
EUR 375.6

Human anti-cyclic citrullinated peptide(CCP)ELISA Kit

GA-E0580HM-48T 48T
EUR 346.8

Human anti-cyclic citrullinated peptide(CCP)ELISA Kit

GA-E0580HM-96T 96T
EUR 559.2

Human anti-cyclic citrullinated peptide(CCP)ELISA Kit

QY-E02624 96T
EUR 433.2

Human anti-cyclic citrullinated peptide,CCP ELISA Kit

YLA2279HU-48T 48T
EUR 435

Human anti-cyclic citrullinated peptide,CCP ELISA Kit

YLA2279HU-96T 96T
EUR 562.5

Human Delta Sleep-Inducing Peptide (dSIP) Peptide

20-abx066303
  • EUR 794.40
  • EUR 326.40
  • EUR 2431.20
  • EUR 944.40
  • EUR 577.20
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Recombinant Human PlGF-3 Protein

PROTP49763-6 25ug
EUR 380.4
Description: PlGF-3 is an angiogenic factor that belongs to the cysteine-knot superfamily of growth factors. PlGF-3 is expressed exclusively in the placenta. It signals through the VEGFR-1/FLT1 receptor and stimulates endothelial cell proliferation and migration. PlGF-3 lacks heparin binding affinity. Recombinant human PlGF-3 is a 45.7 kDa disulfide-linked homodimeric protein of two 203 amino acid polypeptide chains.

Recombinant Human PlGF-1 Protein

PROTP49763-7 25ug
EUR 380.4
Description: PlGF-1 is an angiogenic factor that belongs to the cysteine-knot superfamily of growth factors. PlGF-1 is expressed in placental tissues, colon and mammary carcinomas. It signals through the VEGFR-1/FLT1 receptor and stimulates endothelial cell proliferation and migration. Recombinant human PlGF-1 is a 29.7 kDa disulfide-linked homodimeric protein of two 132 amino acid polypeptide chains.

Recombinant Human PlGF-2 Protein

PROTP49763-8 25ug
EUR 380.4
Description: PLGF-2 is an angiogenic factor that belongs to the cysteine-knot superfamily of growth factors. PLGF-2 is expressed in umbilical vein endothelial cells and placenta. It signals through the VEGFR-1/FLT1 receptor and stimulates endothelial cell proliferation and migration. PlGF-2 also signals through Neuropilin (NP-1) and can bind with high affinity to heparin. Recombinant human PLGF-2 is a 34.0 kDa disulfide-linked homodimeric protein of two 150 amino acid polypeptide chains.

Human Amyloid Beta Peptide 1-40 (Ab1-40) Peptide (BSA)

20-abx651143
  • EUR 376.80
  • EUR 243.60
  • EUR 927.60
  • EUR 410.40
  • EUR 309.60
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Amyloid Beta Peptide 1-40 (Ab1-40) Peptide (OVA)

20-abx651144
  • EUR 577.20
  • EUR 292.80
  • EUR 1646.40
  • EUR 678.00
  • EUR 410.40
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Amyloid Beta Peptide 1-40 (Ab1-40) Peptide (KLH)

20-abx651145
  • EUR 410.40
  • EUR 260.40
  • EUR 1078.80
  • EUR 493.20
  • EUR 326.40
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Amyloid Beta Peptide 1-42 (Ab1-42) Peptide (BSA)

20-abx651173
  • EUR 376.80
  • EUR 243.60
  • EUR 978.00
  • EUR 427.20
  • EUR 309.60
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Amyloid Beta Peptide 1-42 (Ab1-42) Peptide (OVA)

20-abx651174
  • EUR 594.00
  • EUR 292.80
  • EUR 1696.80
  • EUR 693.60
  • EUR 427.20
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Amyloid Beta Peptide 1-42 (Ab1-42) Peptide (KLH)

20-abx651842
  • EUR 693.60
  • EUR 309.60
  • EUR 2064.00
  • EUR 828.00
  • EUR 510.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Amyloid Beta Peptide 1-42 (Ab1-42) Peptide (OVA)

20-abx165506
  • EUR 744.00
  • EUR 326.40
  • EUR 2230.80
  • EUR 878.40
  • EUR 543.60
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Amyloid Beta Peptide 1-40 (Ab1-40) Peptide (OVA)

20-abx165634
  • EUR 727.20
  • EUR 309.60
  • EUR 2180.40
  • EUR 861.60
  • EUR 526.80
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Peptide YY (3-36) (human)

H-8585.0500 0.5mg
EUR 327.6
Description: Sum Formula: C180H279N53O54; CAS# [123583-37-9] net

Peptide YY (3-36) (human)

H-8585.1000 1.0mg
EUR 544.8
Description: Sum Formula: C180H279N53O54; CAS# [123583-37-9] net

Human Calcitonin Gene Related Peptide (CGRP) Peptide

20-abx065658
  • EUR 710.40
  • EUR 309.60
  • EUR 2131.20
  • EUR 844.80
  • EUR 526.80
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

LL - 37, Antimicrobial Peptide, human

5-01469 4 x 1mg Ask for price

Prion Peptide (106-126), Human

5-01808 4 x 1mg Ask for price

Human Natriuretic Peptide Precursor B (NPPB) Peptide

20-abx652101
  • EUR 878.40
  • EUR 343.20
  • EUR 2766.00
  • EUR 1062.00
  • EUR 627.60
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Tau Peptide (1-16) (human)

H-8004.0500 0.5mg
EUR 135.6
Description: Sum Formula: C77H120N20O28S3; CAS# [2022956-53-0] net

Tau Peptide (1-16) (human)

H-8004.1000 1.0mg
EUR 205.2
Description: Sum Formula: C77H120N20O28S3; CAS# [2022956-53-0] net

anti- peptide YY antibody

FNab06310 100µg
EUR 702
Description: Antibody raised against peptide YY

Human Pro-Gastrin Releasing Peptide (ProGRP) Peptide

20-abx168685
  • EUR 744.00
  • EUR 326.40
  • EUR 2264.40
  • EUR 895.20
  • EUR 543.60
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Trypsinogen Activation Peptide (TAP) Peptide (BSA)

20-abx651098
  • EUR 309.60
  • EUR 226.80
  • EUR 644.40
  • EUR 326.40
  • EUR 260.40
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Trypsinogen Activation Peptide (TAP) Peptide (OVA)

20-abx651099
  • EUR 309.60
  • EUR 226.80
  • EUR 644.40
  • EUR 326.40
  • EUR 260.40
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Glutaminyl Peptide Cyclotransferase (QPCT) Peptide

20-abx168154
  • EUR 794.40
  • EUR 326.40
  • EUR 2448.00
  • EUR 944.40
  • EUR 577.20
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human C-Type Natriuretic Peptide (NPPC) Peptide (OVA)

20-abx651832
  • EUR 678.00
  • EUR 309.60
  • EUR 1980.00
  • EUR 794.40
  • EUR 493.20
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Gastrin Releasing Peptide Receptor (GRPR) Peptide

20-abx650009
  • EUR 811.20
  • EUR 343.20
  • EUR 2498.40
  • EUR 961.20
  • EUR 577.20
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

ELISA kit for Human PLGF

EK5213 96 tests
EUR 663.6
Description: Enzyme-linked immunosorbent assay kit for quantification of Human PLGF in samples from serum, plasma, tissue homogenates and other biological fluids.

Amyloid ?-Peptide (10-20) (human)

A1038-1 1 mg
EUR 199.2
Description: The amyloid ?-peptide (A?) has a central role in initiating neurodegeneration in Alzheimer disease (AD) 1. It is widely believed to be an incidental catabolic byproduct of the amyloid ? protein precursor (APP) with no normal physiological function.

Amyloid ?-Peptide (10-20) (human)

A1038-10 10 mg
EUR 756
Description: The amyloid ?-peptide (A?) has a central role in initiating neurodegeneration in Alzheimer disease (AD) 1. It is widely believed to be an incidental catabolic byproduct of the amyloid ? protein precursor (APP) with no normal physiological function.

Amyloid ?-Peptide (10-20) (human)

A1038-25 25 mg
EUR 1034.4
Description: The amyloid ?-peptide (A?) has a central role in initiating neurodegeneration in Alzheimer disease (AD) 1. It is widely believed to be an incidental catabolic byproduct of the amyloid ? protein precursor (APP) with no normal physiological function.

Amyloid ?-Peptide (10-20) (human)

A1038-5 5 mg
EUR 477.6
Description: The amyloid ?-peptide (A?) has a central role in initiating neurodegeneration in Alzheimer disease (AD) 1. It is widely believed to be an incidental catabolic byproduct of the amyloid ? protein precursor (APP) with no normal physiological function.

PLGF-2, human recombinant protein

P1056-.01 10 µg
EUR 360
Description: Placenta Growth Factor-2 (PLGF-2) is an angiogenic factor produced in umbilical vein endothelial cells and placenta. PLGF-2 plays important roles in angiogenesis and endothelial cell growth.

PLGF-2, human recombinant protein

P1056-.05 50 µg
EUR 1052.4
Description: Placenta Growth Factor-2 (PLGF-2) is an angiogenic factor produced in umbilical vein endothelial cells and placenta. PLGF-2 plays important roles in angiogenesis and endothelial cell growth.

Conclusion: Nearly half of the patients surveyed reported vague or non-compliance with their oral anticancer agent. Qualitative interviews identified several important themes, many of which are not recognized by physicians and nurse practitioners. These findings highlight the need for the patient and health care professional interventions to improve patient adherence.